Tempest Therapeutics, INC 8-K filings

Tempest Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Tempest Therapeutics has amended its Rights Agreement to grant the board more administrative control and stockholders have approved a reverse stock split.

Tempest Therapeutics reported third quarter 2024 financial results, highlighted by FDA approval to proceed with a pivotal Phase 3 trial for amezalpat in combination therapy for liver cancer and a collaboration with Roche.

Tempest Therapeutics has amended its stockholder rights plan to extend its duration and entered into a clinical supply agreement with Roche for its Phase 3 trial.

Tempest Therapeutics reported positive survival data for amezalpat in liver cancer and provided a financial update for the second quarter of 2024.

Tempest Therapeutics reports a six-month improvement in median overall survival for its drug amezalpat in a first-line liver cancer study.

Tempest Therapeutics held its 2024 Annual Meeting of Stockholders on June 13, 2024, where key proposals including the election of directors and ratification of the accounting firm were approved.

Tempest Therapeutics announced its first quarter 2024 financial results, highlighted by advancements in their clinical programs and a cash balance of $32.3 million.

Tempest Therapeutics announced positive clinical data for its lead drug candidate, TPST-1120, in liver cancer and provided a financial update for the year ended December 31, 2023.